epcoritamab
abbvie,genmab
['epcore,nhl,3', 'nhl', 'epcore,nhl,1', 'cml']
#17icml epcore nhl-1 phase ii dose expansion. determined dose: 48mg. bispecific gives subcutaneously. crr 39%. pfs by best response per irc in cr group is not achieved. 
Happily married. Hematologist & SC Transplanter. field of interest: lymphoma-myeloma &chemoresistance biomarkers. @HematoClinicBCN @hematosantpau.@GELL01433166